Published in Neurochem Res on May 15, 2009
Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys (2010) 1.67
Phospholipase D: enzymology, functionality, and chemical modulation. Chem Rev (2011) 1.66
Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol (2013) 1.34
The structure of dopamine induced alpha-synuclein oligomers. Eur Biophys J (2010) 1.08
Phospholipase D in brain function and Alzheimer's disease. Biochim Biophys Acta (2010) 1.06
Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol (2011) 1.01
Complex molecular regulation of tyrosine hydroxylase. J Neural Transm (Vienna) (2014) 0.85
Binding of Dopamine to Alpha-Synuclein is Mediated by Specific Conformational States. J Am Soc Mass Spectrom (2013) 0.83
Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's disease. CNS Neurol Disord Drug Targets (2012) 0.81
The Aggregation of Huntingtin and α-Synuclein. J Biophys (2012) 0.80
Inflaming the diseased brain: a role for tainted melanins. Biochim Biophys Acta (2015) 0.79
The neurotransmitter serotonin interrupts α-synuclein amyloid maturation. Biochim Biophys Acta (2011) 0.79
A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD). J Biol Chem (2013) 0.79
SPECT molecular imaging in Parkinson's disease. J Biomed Biotechnol (2012) 0.79
Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons. Neural Regen Res (2014) 0.78
Changes in plasma membrane surface potential of PC12 cells as measured by Kelvin probe force microscopy. PLoS One (2012) 0.78
Neuromelanin enhances the toxicity of α-synuclein in SK-N-SH cells. J Neural Transm (Vienna) (2011) 0.77
In silico modeling of the effects of alpha-synuclein oligomerization on dopaminergic neuronal homeostasis. BMC Syst Biol (2014) 0.76
Catecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein. Diagnostics (Basel) (2013) 0.75
α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology. J Neuroinflammation (2016) 0.75
A hyperbranched dopamine-containing PEG-based polymer for the inhibition of α-synuclein fibrillation. Biochem Biophys Res Commun (2015) 0.75
Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Des Devel Ther (2017) 0.75
Structural and functional properties of prefibrillar α-synuclein oligomers. Sci Rep (2016) 0.75
A spontaneous deletion of α-synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: effects on alcohol consumption. Synapse (2013) 0.75
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med (2012) 3.31
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci (2008) 1.86
Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci (2005) 1.83
The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta (2007) 1.83
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J (2007) 1.50
Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem (2003) 1.38
Enrichment of prion protein in exosomes derived from ovine cerebral spinal fluid. Vet Immunol Immunopathol (2008) 1.36
Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J Mol Biol (2004) 1.32
Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A (2009) 1.29
Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J (2004) 1.29
Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol (2006) 1.23
ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem (2008) 1.20
Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol (2005) 1.19
Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med (2009) 1.19
Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein. Biochemistry (2008) 1.18
Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol (2008) 1.17
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem (2006) 1.16
Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem (2003) 1.14
Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem (2005) 1.14
Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol (2005) 1.12
Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem (2006) 1.10
Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic Biol Med (2009) 1.09
The structure of dopamine induced alpha-synuclein oligomers. Eur Biophys J (2010) 1.08
Solution conformation and heparin-induced dimerization of the full-length extracellular domain of the human amyloid precursor protein. J Mol Biol (2006) 1.07
Mouse-adapted sporadic human Creutzfeldt-Jakob disease prions propagate in cell culture. Int J Biochem Cell Biol (2008) 1.06
Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry (2007) 1.06
The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. J Biol Chem (2009) 1.05
Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem (2004) 1.04
A serial analysis of gene expression profile of the Alzheimer's disease Tg2576 mouse model. Neurotox Res (2009) 1.03
Correlative studies support lipid peroxidation is linked to PrP(res) propagation as an early primary pathogenic event in prion disease. Brain Res Bull (2005) 1.03
Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J Inorg Biochem (2006) 1.02
Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One (2011) 1.02
6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J Biol Chem (2006) 1.01
Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem (2004) 1.00
Monitoring the prevention of amyloid fibril formation by alpha-crystallin. Temperature dependence and the nature of the aggregating species. FEBS J (2007) 0.99
Conformational detection of prion protein with biarsenical labeling and FlAsH fluorescence. Biochem Biophys Res Commun (2009) 0.99
Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel (2008) 0.99
Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J Neurochem (2004) 0.99
The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. Mol Neurobiol (2008) 0.99
Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem Sci (2006) 0.98
Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys J (2007) 0.98
Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy. J Am Chem Soc (2008) 0.97
Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. J Mol Biol (2009) 0.96
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J Exp Med (2012) 0.96
A domain level interaction network of amyloid precursor protein and Abeta of Alzheimer's disease. Proteomics (2010) 0.96
Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease. FEBS Lett (2010) 0.94
Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein. J Neurosci (2002) 0.94
Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions. J Mol Biol (2006) 0.93
Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 0.93
Neurotoxicity from glutathione depletion is dependent on extracellular trace copper. J Neurosci Res (2003) 0.93
Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. Biochim Biophys Acta (2008) 0.92
Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging (2005) 0.89
Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.88
Residues surrounding the glycosylphosphatidylinositol anchor attachment site of PrP modulate prion infection: insight from the resistance of rabbits to prion disease. J Virol (2010) 0.88
The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains. Brain Res (2011) 0.88
Copper binding to the Alzheimer's disease amyloid precursor protein. Eur Biophys J (2007) 0.88
Stereospecific interactions are necessary for Alzheimer disease amyloid-β toxicity. Neurobiol Aging (2009) 0.87
Amyloid-β: the seeds of darkness. Int J Biochem Cell Biol (2011) 0.87
sAPPα rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury. J Neurochem (2012) 0.86
Amyloid precursor protein is required for normal function of the rod and cone pathways in the mouse retina. PLoS One (2012) 0.86
Alleviating transcriptional inhibition of the norepinephrine slc6a2 transporter gene in depolarized neurons. J Neurosci (2010) 0.85
An update on the toxicity of Abeta in Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.85
Alois Alzheimer and Alzheimer's disease: a centennial perspective. J Neurochem (2006) 0.85
Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C: possible role of heparan sulfate oligosaccharides derived from glypican-1 by ascorbate-induced, nitric oxide (NO)-catalyzed degradation. J Biol Chem (2011) 0.85
Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. J Alzheimers Dis (2010) 0.84
Iron inhibits neurotoxicity induced by trace copper and biological reductants. J Biol Inorg Chem (2004) 0.84
Possible mechanisms of APP-mediated oxidative stress in Alzheimer's disease. Free Radic Biol Med (2002) 0.84
Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study. Mol Biosyst (2014) 0.84
Stimulus pattern dependence of the Alzheimer's disease amyloid-beta 42 peptide's inhibition of long term potentiation in mouse hippocampal slices. Brain Res (2009) 0.83
Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease. Mol Biosyst (2008) 0.83
Conservation of a glycine-rich region in the prion protein is required for uptake of prion infectivity. J Biol Chem (2010) 0.83
In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol (2009) 0.83
Identification of a novel amyloid precursor protein processing pathway that generates secreted N-terminal fragments. FASEB J (2012) 0.82
Evidence for a copper-binding superfamily of the amyloid precursor protein. Biochemistry (2002) 0.82
α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease. J Neurochem (2014) 0.82
In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. Nucl Med Biol (2012) 0.82
Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Brain Res Mol Brain Res (2004) 0.81
Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). Brain Res (2002) 0.81
Structure of Alzheimer's disease amyloid precursor protein copper-binding domain at atomic resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.81
Detection of prion epitopes on PrP and PrP of transmissible spongiform encephalopathies using specific monoclonal antibodies to PrP. Immunol Cell Biol (2005) 0.81
Cu2+-induced modification of the kinetics of A beta(1-42) channels. Am J Physiol Cell Physiol (2003) 0.81
SERF protein is a direct modifier of amyloid fiber assembly. Cell Rep (2012) 0.81
Diverse fibrillar peptides directly bind the Alzheimer's amyloid precursor protein and amyloid precursor-like protein 2 resulting in cellular accumulation. Brain Res (2003) 0.80
Evidence for prion protein expression in enteroglial cells of the myenteric plexus of mouse intestine. Auton Neurosci (2008) 0.80
Evaluation of the effects of treatment with sAPPα on functional and histological outcome following controlled cortical impact injury in mice. Neurosci Lett (2012) 0.80
Amyloid precursor protein (APP)/APP-like protein 2 (APLP2) expression is required to initiate endosome-nucleus-autophagosome trafficking of glypican-1-derived heparan sulfate. J Biol Chem (2014) 0.79
APP involvement in retinogenesis of mice. Acta Neuropathol (2010) 0.79
Chronic exposure to high levels of zinc or copper has little effect on brain metal homeostasis or Abeta accumulation in transgenic APP-C100 mice. Cell Mol Neurobiol (2009) 0.79
Gene knockout of tau expression does not contribute to the pathogenesis of prion disease. J Neuropathol Exp Neurol (2011) 0.79
The neurotransmitter serotonin interrupts α-synuclein amyloid maturation. Biochim Biophys Acta (2011) 0.79
The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding. Biosci Rep (2013) 0.79